The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Apremilast Most Helpful for Mild to Moderate Psoriatic Arthritis

Apremilast Most Helpful for Mild to Moderate Psoriatic Arthritis

May 18, 2020 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Apremilast, an oral phosphodiesterase 4 inhibitor used to treat psoriatic arthritis (PsA), has a benign safety profile and, thus, is a welcome therapeutic option. Recent research delivers more evidence apremilast helps PsA patients who have moderate—as opposed to high—disease activity at baseline achieve treatment targets at week 52.

You Might Also Like
  • Long-Term Apremilast Promising for Psoriatic Arthritis
  • Apremilast Effective for Psoriatic Arthritis
  • Study Results for 9 New Psoriatic Arthritis Drugs
Also By This Author
  • The Gut Microbiome Influences Postmenopausal Bone Loss

The study by Philip J. Mease, MD, director of rheumatology research at the Swedish Medical Center, Seattle, and colleagues also revealed that partial improvements by week 16 were associated with achieving treatment targets at week 52. The results, published online Jan. 7 in Arthritis Care & Research, indicate that patients receiving apremilast who achieved Clinical Disease Activity in Psoriatic Arthritis (cDAPSA) targets by week 52 also had no or mild arthritis and other PsA manifestations. Taken together, the data suggest, although apremilast may be a good option for patients with mild to moderate disease, biologics may be a better choice for patients with severe disease.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Conversations with Patients
“In some ways, PsA is more complex and variegated than other rheumatic diseases because of the multiple clinical domains affected by the disease,” says Dr. Mease. For many patients, enthesitis is the worst part of the syndrome. For other patients, the skin and nail disease are so severe they cause physical disability and mental pain.

In the study, Dr. Mease and colleagues found 46.9% of patients who started with moderate disease activity at baseline achieved treatment targets, whereas only 24.9% of patients who started with high disease activity achieved the same. “If the patient started in a state of very high disease activity, they had a tougher time getting to an optimal state,” says Dr. Mease.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

According to Dr. Mease, this finding, in addition to the fact that the week 16 mark is a meaningful predictor of a patient’s ability to get to a low disease state on apremilast, is meaningful addition to conversations with patients.

cDAPSA as a Measure of Disease
“We struggle to have composite measures that take into account the full impact of the disease,” says Dr. Mease.

This struggle can be especially difficult the case of patients with concomitant fibromyalgia and enthesitis. Thus, rheumatologists continue to seek measures that can be used reliably to ascertain disease activity, track disease activity and track patient progress. In all cases, the treatment goal is a state of minimal disease activity defined by low activity assessed by tender/swollen joint counts, tender entheseal points, Psoriasis Area and Severity Index or body surface area, patient pain and global activity Visual Analog Scale, and functional evaluation by Health Assessment Questionnaire.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Conditions Tagged With: apremilast, cDAPSA, Clinical Disease Activity in Psoriatic Arthritis (cDAPSA), PsA, PsA Resource Center, Psoriatic Arthritis

You Might Also Like:
  • Long-Term Apremilast Promising for Psoriatic Arthritis
  • Apremilast Effective for Psoriatic Arthritis
  • Study Results for 9 New Psoriatic Arthritis Drugs
  • Apremilast Proves Effective for PsA with Skin Involvement

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)